Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATNM |
---|---|---|
09:32 ET | 7905 | 8.26 |
09:34 ET | 100 | 8.26 |
09:36 ET | 1535 | 8.2 |
09:39 ET | 200 | 8.19 |
09:41 ET | 1000 | 8.145 |
09:43 ET | 666 | 8.17 |
09:45 ET | 549 | 8.19 |
09:48 ET | 1300 | 8.15 |
09:54 ET | 500 | 8.09 |
09:56 ET | 100 | 8.08 |
09:57 ET | 350 | 8.125 |
09:59 ET | 1700 | 8.11 |
10:01 ET | 525 | 8.16 |
10:03 ET | 250 | 8.15 |
10:06 ET | 1100 | 8.13 |
10:08 ET | 100 | 8.13 |
10:10 ET | 100 | 8.1 |
10:14 ET | 100 | 8.13 |
10:15 ET | 1400 | 8.16 |
10:17 ET | 100 | 8.17 |
10:19 ET | 200 | 8.17 |
10:21 ET | 825 | 8.16 |
10:24 ET | 100 | 8.16 |
10:26 ET | 1300 | 8.17 |
10:28 ET | 1206 | 8.1528 |
10:30 ET | 200 | 8.1586 |
10:32 ET | 1385 | 8.12 |
10:33 ET | 395 | 8.0821 |
10:35 ET | 100 | 8.04 |
10:37 ET | 1100 | 8.12 |
10:39 ET | 300 | 8.08 |
10:46 ET | 100 | 8.075 |
10:53 ET | 871 | 8.07 |
10:55 ET | 100 | 8.045 |
11:06 ET | 799 | 8.04 |
11:09 ET | 4599 | 8.15 |
11:11 ET | 952 | 8.125 |
11:13 ET | 102 | 8.153 |
11:15 ET | 200 | 8.1049 |
11:18 ET | 100 | 8.13 |
11:20 ET | 300 | 8.12 |
11:22 ET | 800 | 8.14 |
11:24 ET | 600 | 8.12 |
11:27 ET | 200 | 8.12 |
11:29 ET | 100 | 8.12 |
11:31 ET | 200 | 8.1125 |
11:33 ET | 100 | 8.1 |
11:36 ET | 200 | 8.11 |
11:38 ET | 200 | 8.11 |
11:44 ET | 11360 | 8.08 |
11:47 ET | 100 | 8.05 |
11:49 ET | 100 | 8.055 |
11:54 ET | 300 | 8.06 |
11:56 ET | 300 | 8.055 |
12:00 ET | 100 | 8.03 |
12:03 ET | 440 | 8.05 |
12:12 ET | 100 | 8.06 |
12:14 ET | 601 | 8.05 |
12:16 ET | 7692 | 8 |
12:21 ET | 522 | 7.98 |
12:23 ET | 5901 | 7.95 |
12:25 ET | 929 | 7.95 |
12:27 ET | 400 | 7.9 |
12:30 ET | 1509 | 7.95 |
12:32 ET | 725 | 7.91 |
12:36 ET | 600 | 7.93 |
12:38 ET | 1200 | 7.96 |
12:39 ET | 2498 | 7.99 |
12:45 ET | 500 | 8 |
12:50 ET | 860 | 7.99 |
12:52 ET | 395 | 7.99 |
12:54 ET | 200 | 8.01 |
12:56 ET | 1100 | 7.98 |
01:12 ET | 100 | 8.02 |
01:14 ET | 100 | 7.98 |
01:15 ET | 2800 | 8.0245 |
01:17 ET | 200 | 8.03 |
01:26 ET | 131 | 8.011 |
01:30 ET | 500 | 7.99 |
01:32 ET | 600 | 8 |
01:37 ET | 100 | 8 |
01:42 ET | 1049 | 8.0061 |
01:48 ET | 1179 | 7.98 |
01:55 ET | 387 | 8.0058 |
02:02 ET | 7699 | 7.88 |
02:06 ET | 1000 | 7.915 |
02:09 ET | 2000 | 7.92 |
02:11 ET | 400 | 7.9498 |
02:18 ET | 100 | 7.95 |
02:20 ET | 700 | 8 |
02:22 ET | 200 | 7.975 |
02:24 ET | 2904 | 7.98 |
02:26 ET | 200 | 8 |
02:27 ET | 275 | 8.0014 |
02:31 ET | 100 | 8.015 |
02:33 ET | 1254 | 8.02 |
02:36 ET | 275 | 8.0063 |
02:38 ET | 700 | 8.01 |
02:42 ET | 100 | 8.015 |
02:45 ET | 500 | 7.96 |
02:47 ET | 644 | 8 |
02:51 ET | 300 | 7.995 |
02:56 ET | 300 | 7.99 |
03:00 ET | 570 | 8.03 |
03:02 ET | 700 | 7.9708 |
03:05 ET | 100 | 7.9701 |
03:07 ET | 221 | 7.98 |
03:12 ET | 1000 | 8.01 |
03:14 ET | 100 | 8.0125 |
03:16 ET | 300 | 8 |
03:20 ET | 100 | 7.98 |
03:21 ET | 1000 | 7.9701 |
03:23 ET | 500 | 7.97 |
03:25 ET | 1300 | 7.93 |
03:27 ET | 2300 | 7.925 |
03:30 ET | 587 | 7.905 |
03:34 ET | 300 | 7.9 |
03:36 ET | 300 | 7.9 |
03:38 ET | 349 | 7.89 |
03:39 ET | 919 | 7.88 |
03:41 ET | 2382 | 7.94 |
03:43 ET | 300 | 7.97 |
03:48 ET | 950 | 7.96 |
03:50 ET | 4105 | 7.87 |
03:52 ET | 800 | 7.91 |
03:54 ET | 3076 | 7.93 |
03:56 ET | 733 | 7.91 |
03:57 ET | 1511 | 7.95 |
03:59 ET | 1701 | 7.93 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Actinium Pharmaceuticals Inc | 240.7M | -4.6x | --- |
Eliem Therapeutics Inc | 241.2M | -15.9x | --- |
ESSA Pharma Inc | 242.7M | -8.3x | --- |
Zura Bio Ltd | 243.9M | -2.3x | --- |
Q32 Bio Inc | 238.4M | -0.8x | --- |
Pyxis Oncology Inc | 231.1M | -2.8x | --- |
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $240.7M |
---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.22 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -4.6x |
Price/Sales (TTM) | 2,971.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.